The firm is scrutinizing the sale of Forte Biosciences (NASDAQ: FBRX) to argenx at $77.00 per share, alongside the acquisition of Arcosa (NYSE: ACA) by CRH for $150.00 per share. Additionally, the merger between Bio Green Med Solution (NASDAQ: BGMS) and Future NRG Sdn. Bhd. has drawn similar legal attention. Halper Sadeh attorneys suggest these deals may include terms that unfairly disadvantage minority shareholders or discourage superior competing offers.

Legal representatives for the firm are currently evaluating whether the proposed terms offer adequate consideration to the public. The investigations focus on whether board members prioritized personal financial benefits over their obligations to shareholders. The firm has signaled its intent to pursue increased compensation or additional corporate disclosures, operating on a contingent fee basis for those impacted by these transactions.